Travere Therapeutics, Inc.
News
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on September 10, 2024, the Compensation Committee of its Board of Directors granted...\n more…
Canaccord Genuity Group Increases Travere Therapeutics (NASDAQ:TVTX) Price Target to $23.00
Ticker Report Travere Therapeutics (NASDAQ:TVTX - Get Free Report) had its price target raised by research analysts at Canaccord Genuity Group from $18.00 to $23.00 in a report issued on Tuesday, Benzinga reports...\n more…
Eric M. Dube Sells 21,125 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock
Ticker Report Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CEO Eric M. Dube sold 21,125 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average...\n more…